依托考昔的治疗骨关节炎的临床疗效与安全性评价解读.pptVIP

依托考昔治疗骨关节炎的临床疗效与安全性评价;EMEA United Kingdom* 4/02 Sweden 9/02 Bahrain/Kuwait/UAE 11/02 Ireland 11/02 Finland 2/03 Cyprus 3/03 Norway 4/03 Denmark 5/03 Netherlands 5/03 Qatar 6/03 Gibraltar 8/03 Malta 8/03 Iceland 9/03 Luxembourg 12/03 Saudi Arabia 1/04 Belgium 1/04 Italy* 3/04 Portugal 4/04 Israel 9/04 Germany* 9/04 Estonia 9/04 Greece 1/05 Jordan 1/05 Spain* 1/05 Slovakia 1/05 Romania 8/05 Lithuania 8/05 Latvia 9/05 Oman 1/06 Morocco 1/06 Libya 3/06 South Africa 10/07 Hungary 01/08 ;适应症;选择性COX-2抑制剂-依托考昔;口服24分钟起效 1小时达血药浓度高峰 生物利用度近100% 半衰期约为22小时 ;试验筛选;a≤325 mg/day. ARA=美国风湿协会; COX=环氧化酶. 源自 B